Unique and New Medicinal Product
- Exclusive product
- Patented in Europe/Japan/Canada/USA/China/India
- High annual turnover
- No similar competition
- Worldwide potential
- Potential to be sold over the counter (OTC)
A remarkable opportunity has emerged for an established pharmaceutical company to acquire a newly-developed and highly-regarded medicine which has been created by this business to treat viral infections.
Specifically, the medicine treats respiratory virus infections including but not limited to: The Influenza virus, Rhinovirus (common cold) and The Respiratory Syncytial Virus (RSV). The health and economic burdens of these infections – particularly influenza – can be devastating. Respiratory viral infections cause high morbidity and mortality of patients with chronic illness such as chronic obstructive airway diseases.
The new therapy has far reaching effects, with a low cost of goods. The capsules are advantageous in that they overcome the difficulties encountered by seasonal viral mutations and are effective at any stage of illness. There is a potential for the drug to be purchased over the counter (OTC). Having undergone the primary stage of development, this product is now available and ready to be trialled on a large scale.
Currently prescribed locally and privately, the product has allowed the vendor to generate high yearly takings. The buyer is presented with a phenomenal product which is guaranteed to thrive within the pharmaceutical industry and help generate a high annual income.
For sale is the medicinal product created by the current vendor: a product which would thrive under a large pharmaceutical business. As there is no property attached to this sale it means the drug can be purchased by an individual or company from any location in the world.
The business is relocatable to a place of the new buyers choosing/convenience and offers an excellent runway for additional growth. The new drug was tested on animals, and humans – ensuring its proven success and the data generated from this was presented to the regulator Medicines and Healthcare Products Regulatory Agency (MHRA). It is made in capsular form and is stable: it is an oral medication and in regular use privately
Mastropix Ltd has a number of initiatives that will fuel further progression. Creating an online presence through a professional website and complimentary social media platforms would help to again extend the overseas client base, particularly in countries it does not yet operate in. Considering that the components of new drugs are available at low costs, and based on data available from USA market; we suggest that pricing of the prescription drug is about £20 for low strength and £30 for high strength packs covering a course of 5 days. Setting up an additional office in a country where the demand for life-saving medicine exceeds supply.
Ideal for a business owner already working within the industry, there is vast opportunity for expansion through acquisition. Further initiatives could be implemented by a new owner to grow its market. Actively approaching more private clients and explaining the drug in detail would help to reach out to those who need what the tablet has to offer.
- Fully relocatable
- Wide area of operations
- Patented in multiple countries